Methotrexate and 7-hydroxymethotrexate: Serum level monitoring by high-performance liquid chromatography

C. Canfell; Wolfgang Sadee

Methotrexate and 7-hydroxymethotrexate: Serum level monitoring by high-performance liquid chromatography

C. Canfell
, Wolfgang Sadee

Research output: Contribution to journal › Article › peer-review

Abstract

We have developed a reverse-phase high-performance liquid chromatographic assay with ultraviolet detection at 303 nm for methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in serum, plasma, and cerebrospinal fluid. The procedure involves the concentration of MTX and 7-OH-MTX in the aqueous phase by an n-butanol-ether extraction, resulting in a sensitivity of 10-20 nM in serum. Serum levels of MTX correlated well with those obtained by a competitive dihydrofolate reductase binding assay (r = 0.989). The clinical utility of the assay was demonstrated by measuring MTX and 7-OH-MTX serum levels in 42 patient samples.

Original language	English
Pages (from-to)	165-169
Number of pages	5
Journal	Cancer Treatment Reports
Volume	64
Issue number	1
State	Published - Jan 1 1980

Cite this

@article{cc1203f5eada4b6287480161e15edaf4,

title = "Methotrexate and 7-hydroxymethotrexate: Serum level monitoring by high-performance liquid chromatography",

abstract = "We have developed a reverse-phase high-performance liquid chromatographic assay with ultraviolet detection at 303 nm for methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in serum, plasma, and cerebrospinal fluid. The procedure involves the concentration of MTX and 7-OH-MTX in the aqueous phase by an n-butanol-ether extraction, resulting in a sensitivity of 10-20 nM in serum. Serum levels of MTX correlated well with those obtained by a competitive dihydrofolate reductase binding assay (r = 0.989). The clinical utility of the assay was demonstrated by measuring MTX and 7-OH-MTX serum levels in 42 patient samples.",

author = "C. Canfell and Wolfgang Sadee",

year = "1980",

month = jan,

day = "1",

language = "English",

volume = "64",

pages = "165--169",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

number = "1",

}

TY - JOUR

T1 - Methotrexate and 7-hydroxymethotrexate

T2 - Serum level monitoring by high-performance liquid chromatography

AU - Canfell, C.

AU - Sadee, Wolfgang

PY - 1980/1/1

Y1 - 1980/1/1

N2 - We have developed a reverse-phase high-performance liquid chromatographic assay with ultraviolet detection at 303 nm for methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in serum, plasma, and cerebrospinal fluid. The procedure involves the concentration of MTX and 7-OH-MTX in the aqueous phase by an n-butanol-ether extraction, resulting in a sensitivity of 10-20 nM in serum. Serum levels of MTX correlated well with those obtained by a competitive dihydrofolate reductase binding assay (r = 0.989). The clinical utility of the assay was demonstrated by measuring MTX and 7-OH-MTX serum levels in 42 patient samples.

AB - We have developed a reverse-phase high-performance liquid chromatographic assay with ultraviolet detection at 303 nm for methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in serum, plasma, and cerebrospinal fluid. The procedure involves the concentration of MTX and 7-OH-MTX in the aqueous phase by an n-butanol-ether extraction, resulting in a sensitivity of 10-20 nM in serum. Serum levels of MTX correlated well with those obtained by a competitive dihydrofolate reductase binding assay (r = 0.989). The clinical utility of the assay was demonstrated by measuring MTX and 7-OH-MTX serum levels in 42 patient samples.

UR - https://www.scopus.com/pages/publications/0018863416

M3 - Article

C2 - 7379052

AN - SCOPUS:0018863416

SN - 0361-5960

VL - 64

SP - 165

EP - 169

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

IS - 1

ER -

Methotrexate and 7-hydroxymethotrexate: Serum level monitoring by high-performance liquid chromatography

Abstract

Other files and links

Fingerprint

Cite this